Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study

Basit Öğe Kaydı
dc.authoridTUNC, Abdulkadir/0000-0002-9747-5285
dc.authoridAydin Turkoglu, Sule/0000-0001-8616-832X
dc.contributor.authorTunc, Abdulkadir
dc.contributor.authorYetkin, Mehmet Fatih
dc.contributor.authorSeferoglu, Meral
dc.contributor.authorInanc, Yilmaz
dc.contributor.authorSivaci, Ali Ozhan
dc.contributor.authorTurkoglu, Sule Aydin
dc.contributor.authorBaydar, Caner
dc.date.accessioned2024-09-25T19:58:58Z
dc.date.available2024-09-25T19:58:58Z
dc.date.issued2024
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractBackground: This study investigates the gap in understanding the dynamics of recurring disease activity (RDA) in RRMS patients after fingolimod (FGL) treatment discontinuation. The aim is to investigate RDA in RRMS patients after stopping FGL, aiming to improve management and comprehension of disease progression post-treatment. Methods: In this multicenter, retrospective study, data from 172 of 944 RRMS patients aged 18-55, across nine centers in Turkey, who discontinued FGL treatment, were analyzed. The collected data included EDSS scores, annualized relapse rates (ARR), lymphocyte counts, and MRI findings, with follow-up assessments conducted at 6 months, 1 year, and up to 2 years. Results: RDA was observed in 31.9 % of patients, with incidences of rebound and reactivation at 20.3 % and 11.6 %, respectively. Factors like younger age, longer treatment duration, lower lymphocyte counts, and higher lesion burden increased RDA risk. Notably, 52.9 % of pregnant patients experienced RDA (16.4 % of the overall RDA group), with rebound occurring in six and reactivation in three. Patients with RDA had longer medication-free intervals and increased ARR. Discontinuation reasons varied, with disease progression linked to a lower RDA risk. Conclusion: Findings highlight the necessity for personalized management and vigilant monitoring after FGL discontinuation in RRMS patients, offering critical insights into RDA risk factors, and the complex interplay between treatment cessation, pregnancy, and disease progression.en_US
dc.identifier.doi10.1016/j.msard.2024.105757
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid38972107en_US
dc.identifier.scopus2-s2.0-85197547224en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2024.105757
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13834
dc.identifier.volume88en_US
dc.identifier.wosWOS:001268863300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGuzel, Vildan
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis And Related Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectMultiple sclerosisen_US
dc.subjectRelapsing-remittingen_US
dc.subjectFingolimod hydrochlorideen_US
dc.subjectDisease reactivationen_US
dc.subjectPregnancyen_US
dc.subjectTreatment outcomeen_US
dc.titleRecurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu